Gilead’s Subsidiary Ravens Sub Extends Tender Offer for Arcellx at $115 per Share

Why It Matters

The deal sets a premium exit price for ACLX shareholders while introducing contingent upside, and it creates timing and delivery risks for option writers under NSCC protect provisions.

Key Takeaways

• Ravens Sub offers $115 cash per ACLX share plus $5 CVR
• Offer deadline extended to 5 p.m. ET April 27, 2026
• ACLX/1ACLX options remain unadjusted; no CVR delivery required
• Merger could convert all ACLX shares to cash plus CVR
• Option writers face timing risk under NSCC protect provisions

Pulse Analysis

The extended tender offer from Ravens Sub, the Gilead‑controlled vehicle, provides ACLX shareholders a clear cash component of $115 per share and an additional $5 contingent‑value right (CVR) tied to future milestones. By pushing the expiration to April 27, the acquirer gives investors extra time to evaluate the premium relative to ACLX’s recent trading range, while signaling confidence in the company’s pipeline that could trigger the CVR payout. This structure not only offers immediate liquidity but also preserves upside potential if the biotech’s development goals are achieved, a common tactic in high‑growth life‑science transactions.

For options market participants, the announcement introduces a nuanced risk profile. ACLX/1ACLX call options will not be adjusted to require CVR delivery, meaning holders must exercise before the tender deadline to retain entitlement. Uncovered writers and short futures positions face timing risk under NSCC’s “protect” provisions; failure to deliver the underlying shares promptly could trigger liability. Market makers and clearing members should therefore reassess their hedging strategies and ensure sufficient inventory to meet settlement obligations, especially given the one‑business‑day settlement cycle for exercised options.

Strategically, Gilead’s move through Ravens Sub reflects a broader trend of large pharma firms consolidating promising cell‑therapy assets at premium valuations. The merger intent, once consummated, will streamline ACLX’s shareholder base and integrate its technology into Gilead’s pipeline, potentially accelerating product commercialization. Investors should monitor the milestone criteria governing the CVR, as the $5 payout can materially affect the effective acquisition price. Additionally, any delay or alteration in the merger timeline could impact option adjustments under OCC Rule 2803, influencing market pricing and volatility ahead of the final closing date.

Deal Summary

Ravens Sub, Inc., a wholly‑owned subsidiary of Gilead Sciences, Inc., announced an extended tender offer to purchase all outstanding Arcellx, Inc. (ACLX) common shares for $115 cash per share plus a contingent‑value right. The offer expires on April 27, 2026.